Loading...

APC/Cyanine7 anti-mouse CD62L Antibody APC/Cyanine7 anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL14_APCCy7_031010
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC/Cyanine7 (red histogram) or rat IgG2a FITC isotype control (blue histogram).
  • MEL14_APCCy7_031010
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC/Cyanine7 (red histogram) or rat IgG2a FITC isotype control (blue histogram).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
104427 25 µg DKK559
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104428 100 µg DKK1474
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  2. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  3. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  4. Orvain C, et al. 2022. Arthritis Res Ther. 24:13. PubMed
  5. Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed
  6. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  7. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  8. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  9. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  10. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  11. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  12. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  13. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  14. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  15. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  16. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  17. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  18. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  19. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  20. Fumagalli V, et al. 2020. J Exp Med. :217. PubMed
  21. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  22. Topham T 2010. J Immunol. 184:3841. PubMed
  23. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  24. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  25. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  26. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  27. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  28. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  29. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  30. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  31. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  32. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  33. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  34. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  35. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  36. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  37. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  38. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  39. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  40. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  41. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  42. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  43. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  44. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  45. Frantz PN, et al. 2021. Nat Commun. 12:6277. PubMed
  46. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  47. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  48. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  49. Ryg-Cornejo V, et al. 2016. Cell Rep. 14:68-81. PubMed
  50. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  51. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  52. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  53. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  54. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  55. Orvain C, et al. 2022. Arthritis Res Ther. 24:13. PubMed
  56. Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed
  57. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  58. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  59. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  60. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  61. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  62. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  63. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  64. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  65. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  66. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  67. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  68. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  69. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  70. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  71. Fumagalli V, et al. 2020. J Exp Med. :217. PubMed
  72. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  73. Topham T 2010. J Immunol. 184:3841. PubMed
  74. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  75. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  76. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  77. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  78. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  79. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  80. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  81. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  82. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  83. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  84. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  85. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  86. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  87. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  88. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  89. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  90. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  91. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  92. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  93. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  94. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  95. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  96. Frantz PN, et al. 2021. Nat Commun. 12:6277. PubMed
  97. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  98. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  99. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  100. Ryg-Cornejo V, et al. 2016. Cell Rep. 14:68-81. PubMed
  101. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  102. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_830798 (BioLegend Cat. No. 104427)
AB_830799 (BioLegend Cat. No. 104428)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD62L Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 711™ anti-mouse CD62L MEL-14 FC
Brilliant Violet 785™ anti-mouse CD62L MEL-14 FC
PE/Dazzle™ 594 anti-mouse CD62L MEL-14 FC
APC/Fire™ 750 anti-mouse CD62L MEL-14 FC
TotalSeq™-A0112 anti-mouse CD62L MEL-14 PG
PE/Cyanine7 anti-mouse CD62L MEL-14 FC
Brilliant Violet 650™ anti-mouse CD62L MEL-14 FC
TotalSeq™-C0112 anti-mouse CD62L MEL-14 PG
Ultra-LEAF™ Purified anti-mouse CD62L MEL-14 FC,CyTOF®,IHC-F,IP,CMCD,Block
KIRAVIA Blue 520™ anti-mouse CD62L MEL-14 FC
TotalSeq™-B0112 anti-mouse CD62L MEL-14 PG
Spark Red™ 718 anti-mouse CD62L (Flexi-Fluor™) MEL-14 FC
Spark PLUS B550™ anti-mouse CD62L MEL-14 FC
Spark YG™ 581 anti-mouse CD62L (Flexi-Fluor™) MEL-14 FC
Spark YG™ 593 anti-mouse CD62L (Flexi-Fluor™) Antibody MEL-14 FC
Spark NIR™ 685 anti-mouse CD62L (Flexi-Fluor™) Antibody MEL-14 FC
Spark UV™ 387 anti-mouse CD62L (Flexi-Fluor™) MEL-14 FC
APC anti-mouse CD62L MEL-14 FC
Biotin anti-mouse CD62L MEL-14 FC
FITC anti-mouse CD62L MEL-14 FC
PE anti-mouse CD62L MEL-14 FC
PE/Cyanine5 anti-mouse CD62L MEL-14 FC
Purified anti-mouse CD62L MEL-14 FC,CyTOF®,IHC-F,IP
Alexa Fluor® 488 anti-mouse CD62L MEL-14 FC
Alexa Fluor® 647 anti-mouse CD62L MEL-14 FC
Pacific Blue™ anti-mouse CD62L MEL-14 FC
Alexa Fluor® 700 anti-mouse CD62L MEL-14 FC
APC/Cyanine7 anti-mouse CD62L MEL-14 FC
PerCP/Cyanine5.5 anti-mouse CD62L MEL-14 FC
PerCP anti-mouse CD62L MEL-14 FC
Brilliant Violet 421™ anti-mouse CD62L MEL-14 FC
Brilliant Violet 570™ anti-mouse CD62L MEL-14 FC
Brilliant Violet 605™ anti-mouse CD62L MEL-14 FC
Brilliant Violet 510™ anti-mouse CD62L MEL-14 FC
Purified anti-mouse CD62L (Maxpar® Ready) MEL-14 FC,CyTOF®
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL14_APCCy7_031010
C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC/Cyanine7 (red histogram) or rat IgG2a FITC isotype control (blue histogram).
  • MEL14_APCCy7_031010
    C57BL/6 mouse splenocytes were stained with CD62L (clone MEL-14) APC/Cyanine7 (red histogram) or rat IgG2a FITC isotype control (blue histogram).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
104427 25 µg DKK559
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104428 100 µg DKK1474
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  2. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  3. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  4. Orvain C, et al. 2022. Arthritis Res Ther. 24:13. PubMed
  5. Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed
  6. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  7. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  8. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  9. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  10. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  11. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  12. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  13. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  14. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  15. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  16. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  17. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  18. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  19. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  20. Fumagalli V, et al. 2020. J Exp Med. :217. PubMed
  21. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  22. Topham T 2010. J Immunol. 184:3841. PubMed
  23. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  24. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  25. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  26. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  27. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  28. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  29. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  30. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  31. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  32. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  33. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  34. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  35. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  36. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  37. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  38. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  39. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  40. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  41. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  42. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  43. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  44. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  45. Frantz PN, et al. 2021. Nat Commun. 12:6277. PubMed
  46. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  47. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  48. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  49. Ryg-Cornejo V, et al. 2016. Cell Rep. 14:68-81. PubMed
  50. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  51. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  52. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  53. Gordan S, et al. 2020. Cell Reports. 29(10):3033-3046.e4.. PubMed
  54. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  55. Orvain C, et al. 2022. Arthritis Res Ther. 24:13. PubMed
  56. Koutník J, et al. 2022. Front Immunol. 13:1049033. PubMed
  57. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  58. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  59. Kurosawa M, et al. 2021. Int J Mol Sci. 22:. PubMed
  60. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  61. Lin R, et al. 2020. Sci Rep. 10:14397. PubMed
  62. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  63. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  64. Volpedo G, et al. 2022. NPJ Vaccines. 7:32. PubMed
  65. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  66. Haque M, et al. 2021. STAR Protoc. 2:100264. PubMed
  67. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
  68. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  69. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
  70. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  71. Fumagalli V, et al. 2020. J Exp Med. :217. PubMed
  72. Yu AI, et al. 2020. Cell Rep. 107471:31. PubMed
  73. Topham T 2010. J Immunol. 184:3841. PubMed
  74. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  75. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  76. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  77. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  78. Kinsella S, et al. 2021. Cell Rep. 37:109789. PubMed
  79. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  80. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  81. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  82. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  83. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  84. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  85. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  86. Palazon A, et al. 2017. Cancer Cell. . 10.1016/j.ccell.2017.10.003. PubMed
  87. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  88. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  89. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  90. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  91. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  92. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  93. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  94. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  95. Kim MY, et al. 2022. Nat Commun. 13:3296. PubMed
  96. Frantz PN, et al. 2021. Nat Commun. 12:6277. PubMed
  97. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  98. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  99. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  100. Ryg-Cornejo V, et al. 2016. Cell Rep. 14:68-81. PubMed
  101. Hebbandi Nanjundappa R, et al. 2017. Cell. 171:655. PubMed
  102. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_830798 (BioLegend Cat. No. 104427)
AB_830799 (BioLegend Cat. No. 104428)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
UniProt
View information about CD62L on UniProt.org

Other Formats

View All CD62L Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 711™ anti-mouse CD62L MEL-14 FC
Brilliant Violet 785™ anti-mouse CD62L MEL-14 FC
PE/Dazzle™ 594 anti-mouse CD62L MEL-14 FC
APC/Fire™ 750 anti-mouse CD62L MEL-14 FC
TotalSeq™-A0112 anti-mouse CD62L MEL-14 PG
PE/Cyanine7 anti-mouse CD62L MEL-14 FC
Brilliant Violet 650™ anti-mouse CD62L MEL-14 FC
TotalSeq™-C0112 anti-mouse CD62L MEL-14 PG
Ultra-LEAF™ Purified anti-mouse CD62L MEL-14 FC,CyTOF®,IHC-F,IP,CMCD,Block
KIRAVIA Blue 520™ anti-mouse CD62L MEL-14 FC
TotalSeq™-B0112 anti-mouse CD62L MEL-14 PG
Spark Red™ 718 anti-mouse CD62L (Flexi-Fluor™) MEL-14 FC
Spark PLUS B550™ anti-mouse CD62L MEL-14 FC
Spark YG™ 581 anti-mouse CD62L (Flexi-Fluor™) MEL-14 FC
Spark YG™ 593 anti-mouse CD62L (Flexi-Fluor™) Antibody MEL-14 FC
Spark NIR™ 685 anti-mouse CD62L (Flexi-Fluor™) Antibody MEL-14 FC
Spark UV™ 387 anti-mouse CD62L (Flexi-Fluor™) MEL-14 FC
APC anti-mouse CD62L MEL-14 FC
Biotin anti-mouse CD62L MEL-14 FC
FITC anti-mouse CD62L MEL-14 FC
PE anti-mouse CD62L MEL-14 FC
PE/Cyanine5 anti-mouse CD62L MEL-14 FC
Purified anti-mouse CD62L MEL-14 FC,CyTOF®,IHC-F,IP
Alexa Fluor® 488 anti-mouse CD62L MEL-14 FC
Alexa Fluor® 647 anti-mouse CD62L MEL-14 FC
Pacific Blue™ anti-mouse CD62L MEL-14 FC
Alexa Fluor® 700 anti-mouse CD62L MEL-14 FC
APC/Cyanine7 anti-mouse CD62L MEL-14 FC
PerCP/Cyanine5.5 anti-mouse CD62L MEL-14 FC
PerCP anti-mouse CD62L MEL-14 FC
Brilliant Violet 421™ anti-mouse CD62L MEL-14 FC
Brilliant Violet 570™ anti-mouse CD62L MEL-14 FC
Brilliant Violet 605™ anti-mouse CD62L MEL-14 FC
Brilliant Violet 510™ anti-mouse CD62L MEL-14 FC
Purified anti-mouse CD62L (Maxpar® Ready) MEL-14 FC,CyTOF®
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account